drugset / Trial / NCT06197009
Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Axial Spondyloarthritis
Timeline
- Start
- 2024-07-01
- Primary completion
- 2026-07-01
- Completion
- 2026-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | SCT650C | Monoclonal antibody | 160 mg | Subcutaneous |
| Comparator | SCT650C | Monoclonal antibody | 320 mg | Subcutaneous |